A four-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes has been signed between GSK and 23andMe, a leading consumer genetics company with more than 5 million customers and a portfolio of early stage therapeutic research programmes across a wide range of disease indications. Both companies shall bring existing early stage programmes within the collaboration; GSK will contribute its LRRK2 inhibitor, which is currently in preclinical development as a potential treatment for Parkinsonā€™s disease. All activities will initially be co-funded (50%/50%). GSK has also made a $300 million equity investment in 23andMe, and it will have the right to analyse its database for validation of GSKā€™s existing therapeutic portfolio as well as leverage 23andMeā€™s capabilities for clinical trial recruitment. 23andMe customers voluntary and affirmatively consented to participate to research and mantain the control of their data, which are used after de-identification, so no individual will be identifiable to GSK.